July 2024: A new study, published on July 3, 2024, indicates patients taking semaglutide such as Wegovy may face an increased risk of serious eye injuries, including nonarteritic anterior ischemic optic neuropathy (NAION)
PLEASE REFER TO ANY HEALTH AND PRODUCT WARNINGS BELOW
Waiting ensures: More predictable, longer-lasting results Reduced risk of needing revision surgery due to ongoing weight changes Most patients are advised to maintain a stable weight for several months before proceeding with body contouring, facial surgery, or breast procedures
In the SURPASS-CVOT trial, which compared it with another GLP-1 medication (dulaglutide) rather than a placebo, tirzepatide was non-inferior for major cardiovascular events and reduced the risk of death from any cause by 16%
[16] What began as a side effect quickly became the main event